We have redefined OMERACT US pathology and elementary lesions as well as scoring systems, which are now proposed for OMERACT approval for application in clinical trials.
No takes yet. Share an insight, caveat, or question.
Bruyn et al. (2019) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: